The FDA approved two sickle cell disease gene therapies, Casgevy and Lyfgenia, but patient uptake has been slow due to high costs. The Cell and Gene Therapy Access Model aims to improve patient access through outcomes-based agreements, starting with sickle cell disease treatments.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing